Return to Viral Manufacturing Capabilities

The Lonza Viral facility has been designed to meet US and European regulatory requirements. We have successfully completed audits with the US FDA and the Irish Medicines Board and has experience producing batches for Phase III clinical trials and consistency batches for Biologics License Applications. Our facility was selected by the Adenovirus Reference Material Working Group (ARMWG) to produce adenoviral vector used by researchers worldwide. Major pharmaceutical and biotechnology companies are using this reference material to aid in the development of their own products.